Recently, baricitinib (a Jak1/2/3-selective inhibitor) and upadacitimib (a Jak1/2-selective inhibitor) have also been approved for the treatment of AD in some countries and will become more widely available. The gene discussed is JAK1; the disease is Alzheimer disease.